Iovance Biotherapeutics is a biotechnology business based in the US. Iovance Biotherapeutics shares (IOVA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $8.24 – an increase of 0.73% over the previous week. Iovance Biotherapeutics employs 557 staff and has a trailing 12-month revenue of around $90.9 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $8.24 |
|---|---|
| 52-week range | $5.14 - $18.33 |
| 50-day moving average | $10.08 |
| 200-day moving average | $10.78 |
| Wall St. target price | $23.77 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.48 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $8.14 from 2024-11-20
| 1 week (2024-11-15) | -0.49% |
|---|---|
| 1 month (2024-10-23) | -17.11% |
| 3 months (2024-08-22) | -29.95% |
| 6 months (2024-05-22) | -21.20% |
| 1 year (2023-11-22) | 50.74% |
|---|---|
| 2 years (2022-11-22) | 29.62% |
| 3 years (2021-11-22) | 18.4 |
| 5 years (2019-11-22) | 21.63 |
| Revenue TTM | $90.9 million |
|---|---|
| Gross profit TTM | $0 |
| Return on assets TTM | -29.16% |
| Return on equity TTM | -56.65% |
| Profit margin | 0% |
| Book value | $2.54 |
| Market Capitalization | $2.6 billion |
TTM: trailing 12 months
We're not expecting Iovance Biotherapeutics to pay a dividend over the next 12 months.
Iovance Biotherapeutics's shares were split on a 1:100 basis on 25 September 2013 . So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Iovance Biotherapeutics shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Iovance Biotherapeutics shares which in turn could have impacted Iovance Biotherapeutics's share price.
Over the last 12 months, Iovance Biotherapeutics's shares have ranged in value from as little as $5.14 up to $18.33. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Iovance Biotherapeutics's is 0.594. This would suggest that Iovance Biotherapeutics's shares are less volatile than average (for this exchange).
Iovance Biotherapeutics, Inc. , a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc. ; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.